Nurix Therapeutics Inc [NRIX] stock is trading at $17.48, up 26.67%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NRIX shares have gain 17.63% over the last week, with a monthly amount glided 17.71%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 9, April 2024, Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies. In a post published today on Yahoo Finance, Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL), each with central nervous system (CNS) involvement.
From an analyst’s perspective:
Previously, Barclays started tracking the stock with Overweight rating on March 09, 2023, and set its price target to $20. On February 28, 2023, Oppenheimer initiated with a Outperform rating and assigned a price target of $25 on the stock. Morgan Stanley started tracking the stock assigning a Equal-Weight rating and suggested a price target of $11 on October 11, 2022. Wells Fargo upgraded its rating to a Overweight but $25 remained the price target by the analyst firm on May 31, 2022. Wells Fargo started tracking with a Equal Weight rating for this stock on February 10, 2022, and assigned it a price target of $28. In a note dated December 29, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $62 on this stock.
Nurix Therapeutics Inc [NRIX] stock has fluctuated between $4.22 and $16.11 over the past year. Currently, Wall Street analysts expect the stock to reach $26.5 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $17.48 at the most recent close of the market. An investor can expect a potential return of 51.6% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
Nurix Therapeutics Inc [NASDAQ:NRIX] reported sales of 76.99M for the trailing twelve months, which represents a growth of 123.49%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -2.01%, Pretax Profit Margin comes in at -1.87%, and Net Profit Margin reading is -1.77%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.56 and Total Capital is -0.56. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.02 points at the first support level, and at 12.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.72, and for the 2nd resistance point, it is at 19.97.
Nurix Therapeutics Inc [NRIX] reported earnings per share of -$0.77 for its fiscal quarter that ended on 11/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.57/share, meaning a difference of -$0.2 and a surprise factor of -35.10%. By comparison, the stated earnings for the previous quarter ended on 8/30/2023 were -$0.68 per share as compared to estimates of -$0.76 per share, a difference of $0.08 representing a surprise of 10.50%.
Ratios To Look Out For
For context, Nurix Therapeutics Inc’s Current Ratio is 3.40. Further, the Quick Ratio stands at 3.40, while the Cash Ratio is 0.63. Considering the valuation of this stock, the price to sales ratio is 11.10, the price to book ratio is 4.25.
Transactions by insiders
Recent insider trading involved van Houte Hans, Chief Financial Officer, that happened on Feb 16 ’24 when 6812.0 shares were sold. Chief Scientific Officer, Hansen Gwenn completed a deal on Jan 30 ’24 to sell 2334.0 shares. Meanwhile, Chief Legal Officer Ring Christine sold 1760.0 shares on Jan 30 ’24.
